Stock Events

Stock Events

Brii Biosciences Limited 

$0.130000
0
+$0.00+0% Tuesday 20:00

Statistics

Day High
0.2459
Day Low
0.2312
52W High
0.2459
52W Low
0.12575
Volume
4,154
Avg. Volume
193
Mkt Cap
95.41M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

20AugExpected
Q4 2023
Q2 2024
Q4 2024
Q2 2025
Q4 2025
Q2 2026
-0.15
-0.1
-0.05
0
Expected EPS
N/A
Actual EPS
-0.0206052

Financials

-1,177.97%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
2.66MRevenue
-31.33MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences is a major player in the development of antiviral drugs, directly competing with Brii Biosciences in the infectious disease market.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals focuses on serious diseases, including viral infections, which overlaps with Brii Biosciences' focus areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals competes in the biopharmaceutical field targeting infectious diseases, similar to Brii Biosciences.
Moderna
MRNA
Mkt Cap55.09B
Moderna is known for its mRNA technology used in vaccines, competing in the infectious disease space where Brii Biosciences is also active.
BioNTech
BNTX
Mkt Cap25.64B
BioNTech competes with Brii Biosciences in the development of treatments and vaccines for infectious diseases.
Arbutus Biopharma
ABUS
Mkt Cap1B
Arbutus Biopharma is involved in antiviral drug development, making it a direct competitor in Brii Biosciences' core market.
Inovio Pharmaceuticals
INO
Mkt Cap133.38M
Inovio Pharmaceuticals focuses on DNA medicines including vaccines for infectious diseases, aligning as a competitor to Brii Biosciences.
Novavax
NVAX
Mkt Cap1.53B
Novavax is involved in the development of vaccines for infectious diseases, directly competing with Brii Biosciences.

About

Brii Biosciences Limited, established in 2017 and headquartered in Beijing, China, is dedicated to advancing therapeutic solutions for infectious diseases and disorders affecting the central nervous system. Their diverse pipeline includes BRII-778 and BRII-732, both progressing through Phase I clinical trials for HIV patients. For Hepatitis B (HBV), they are evaluating BRII-179 and BRII-835 in a combined Phase 2 study; BRII-179 also stands as a recombinant protein-based HBV immunotherapeutic in Phase 1b/2a, while BRII-835 has completed Phase 2 for chronic HBV patients. Additionally, the Amubarvimab/romlusevimab combination therapy is under development for COVID-19. In the CNS arena, BRII-296 targets postpartum depression (PPD) and BRII-297 addresses various depressive disorders. Their anti-infective portfolio features BRII-636, BRII-672, and BRII-693, designed to combat multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections, alongside BRII-658 for MDR/XDR tuberculosis and non-tuberculosis mycobacterial infections.
Show more...
CEO
Zhi Hong
Employees
98
Country
Cayman Islands
ISIN
KYG1645A1094
WKN
000A3CTND

Listings

STU
DE
7SS.STU
HK
HK
2137.HK
MU
DE
7SS.MU
OTC Link
US
BRIBF

0 Comments

Share your thoughts

FAQ

What is Brii Biosciences Limited stock price today?▼
The current price of BRIBF is $0.13 USD — it has increased by +0% in the past 24 hours. Watch Brii Biosciences Limited stock price performance more closely on the chart.
What is Brii Biosciences Limited stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Brii Biosciences Limited stocks are traded under the ticker BRIBF.
Is Brii Biosciences Limited stock price growing?▼
BRIBF stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Brii Biosciences Limited has showed a -45.97% decrease.
What is Brii Biosciences Limited market cap?▼
Today Brii Biosciences Limited has the market capitalization of 95.41M
When is the next Brii Biosciences Limited earnings date?▼
Brii Biosciences Limited is going to release the next earnings report on March 19, 2027.
What were Brii Biosciences Limited earnings last quarter?▼
BRIBF earnings for the last quarter are -0.02 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Brii Biosciences Limited revenue for the last year?▼
Brii Biosciences Limited revenue for the last year amounts to 2.66M USD.
What is Brii Biosciences Limited net income for the last year?▼
BRIBF net income for the last year is -31.33M USD.
How many employees does Brii Biosciences Limited have?▼
As of September 05, 2026, the company has 98 employees.
In which sector is Brii Biosciences Limited located?▼
Brii Biosciences Limited operates in the Health & Wellness sector.
When did Brii Biosciences Limited complete a stock split?▼
Brii Biosciences Limited has not had any recent stock splits.
Where is Brii Biosciences Limited headquartered?▼
Brii Biosciences Limited is headquartered in Beijing, Cayman Islands.